Algorae Pharmaceuticals Limited has released a press release.
NTCELL demonstrates continued reversal of Parkinsons
Filed with ASX ·
6ix hasn’t read this filing yet.
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- LCT JV secures funds to realise the potential of DIABECELL
- LCT starts Phase IIb clinical trial of NTCELL
- LCT completes $2.8m private placement and announces SPP
- LCT receives ethics approval for Phase IIb Parkinsons trial
- NTCELL reverses the progression of Parkinsons disease
Later from Algorae Pharmaceuticals
- LCTs joint venture focuses on US developments
- Group 1 patients successfully treated in Parkinsons trial
- Appendix 4C Quarterly Cash Flow Report 30 September 2016
- Approval granted for group 2 in Parkinsons trial
- Suspension from Official Quotation
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals